Figure 2. Schematic representation of the CTCF protein.
Protein sequences encoded by exons are boxed. 11 ring fingers are indicated by green boxes as also putative AT-hooks by blue boxes (Ensembl). Phosphorylated residues are in black (PhosphoSitePlus), those sensitive to rapamycin are indicated by R (Chen et al., 2009 ) and those phosphorylated by CKII by CKII (El-Kady et al., 2005; Klenova et al., 2001) , sumoylated residues are in red (Kitchen et al., 2010; MacPherson et al., 2009 ), acetylated residue is indicated by Ac (Choudhary et al., 2009 ). The domain containing poly(ADPribosyl)ation sites (PAR) is boxed in red (Farrar et al., 2010) . Residues mutated in tumors are indicated (see further), BT = breast tumor, PT = prostate tumor and WT = Wilms tumor.
Protein
Description CTCF was originally described as a c-myc activator (Klenova et al., 1993) . It is a 727 aa protein with a MW of 82.8 kD, a charge of 8.5 and an iso electric point of 6.95 (Ensembl). The central domain with 11 zinc fingers of the C2H2 type is highly conserved.
Expression
CTCF is an abundant and ubiquitously expressed protein, yet absent in primary spermatocytes (Loukinov et al., 2002) . It is downregulated during differentiation of human myeloid leukemia cells (Delgado et al., 1999; Torrano et al., 2005) . Post-traductional modifications include acetylation (Choudhary et al., 2009) , sumoylation (Kitchen et al., 2010; MacPherson et al., 2009) , phosphorylation, in particular ser604-612 by CKII (El-Kady et al., 2005; Klenova et al., 2001) , and poly(ADPribo)sylation (see figure 2) . The latter modification is lost or decreased in proliferating cells and in BT (Docquier et al., 2009 ) (for sites and role see Farrar et al., 2010 and Yu et al., 2004) . CTCF is a downstream target protein of growth factor-induced pathways and is regulated by EGF and insulin through activation of ERK and AKT signaling cascades (Gao et al., 2007) . It was recently shown to be regulated by NFkB (Lu et al., 2010) .
Localisation
CTCF is localized in the nucleoplasm of proliferating cells with exclusion from the nucleolus. It was detected at the centrosomes and midbody during mitosis (Zhang et al., 2004) . It is associated with the nuclear matrix (Dunn et al., 2003; Yusufzai et al., 2004a ) and the Lamina (Guelen et al., 2008; Ottaviani et al., 2009 ). Nucleolar translocation after growth arrest is accompanied by inhibition of nucleolar transcription (Torrano et al., 2006) . Cytoplasmic expression was described in sporadic breast tumors (Rakha et al., 2004) .
Function
CTCF is an essential protein, since KO mice die before ED 9.5 (Heath et al., 2008 ) (reviewed in Filippova, 2008 and Phillips et al., 2009 ). It interacts with up to 39609 genomic sites (in ES cells) Bao et al., 2007; Barski et al., 2007; Kim et al., 2007) . The 11 Zn fingers would provide flexibility in DNA recognition (Filippova et al., 1996) , the central 4 bind to a consensus DNA sequence (Filippova et al., 1998; Renda et al., 2007) . Multiple interacting proteins were described including RNA polymerase II (Chernukhin et al., 2007) , cohesin (Parelho et al., 2008; Rubio et al., 2008; Wendt et al., 2008) , Suz12 (Li et al., 2008) , CHD8 (Ishihara et al., 2006) , YY1 (Donohoe et al., 2007) , nucleophosmin (Yusufzai et al., 2004b) , Kaiso (Defossez et al., 2005) and Sin3A (Lutz et al., 2000) . Mediating DNA looping (Splinter et al., 2006) could be at the basis of most functions of CTCF. Long range interactions are cell type specific (Hou et al., 2010) and would depend on the chromosomal environment of the CTCF-binding sites, in particular its interaction with other factors (see concept of modular insulators in Weth et al., 2010) . One thoroughly studied factor is the thyroid receptor (Awad et al., 1999; Lutz et al., 2003) . Its chromosomal environment could also explain the multiple (not necessarily exclusive) functions that were described for CTCF, including chromatin barrier (Cuddapah et al., 2008; Witcher et al., 2009 ), promoter insulation from enhancer (Bell et al., 1999) or silencer , transcriptional activation (Gombert et al., 2009 ) (for instance of the tumour suppressor genes INK4A/ARF (Rodriguez et al., 2010) and p53 (Soto-Reyes et al., 2010)), repression (for instance hTERT (Renaud et al., 2005) ), nucleosome positioning (Fu et al., 2008b) , protection from DNA methylation (Mukhopadhyay et al., 2004; Schoenherr et al., 2003; Guastafierro et al., 2008) , preservation of triplet-repeat stability (Cho et al., 2005; Filippova et al., 2001; Libby et al., 2008) , imprinting (Fedoriw et al., 2004; Fitzpatrick et al., 2007) , X chromosome inactivation (Chao et al., 2002) , chromosome "kissing" (Ling et al., 2006) , transvection (Liu et al., 2008) , death signaling (Docquier et al., 2005; Gomes et al., 2010; Li et al., 2007) , replication timing (Bergstrom et al., 2007) , mitotic bookmarking (Burke et al., 2005) or MHC class II gene expression (Majumder et al., 2008) . 
Germinal
Non-coding mutations only.
Somatic
Mutations are rare and include point mutations of Znfingers in breast (BT) (Aulmann et al., 2003) , prostate (PT) and Wilms tumor (WT) (Filippova et al., 2002) and insertion in BT (Aulmann et al., 2003) (see figure  2 ).
Implicated in

Various cancers
Note LOH of CTCF was described in many cancers together with potential tumor suppressor genes (TSG), including E-Cad, since it is part of a larger deletion (Cancer Chromosomes; Sanger institute). In addition to WT (Yeh et al., 2002; Mummert et al., 2005) , BT (Rakha et al., 2004) , PT (Filippova et al., 1998) , LOH was found in laryngeal squamous cell carcinoma (Grbesa et al., 2008) , however, there is no evidence that CTCF is the TSG at 16q22.1 (Rakha et al., 2005) , except possibly in lobular carcinoma in situ of the breast (Green et al., 2009 ). CTCF was also described to be overexpressed in BT (Docquier et al., 2005 ). An indirect role of CTCF in tumor progression is mainly suggested by mutation or aberrant methylation of its bindings sites (reviewed by Recillas-Targa et al., 2006) . Interestingly, a causal link between LOH of CTCF and hypermethylation was proposed by Mummert et al. in 2005, although (Dammann et al., 2010) and laryngeal squamous cell carcinoma (Grbesa et al., 2008) . Hypomethylation was described in bladder cancer (Takai et al., 2001 ). Microdeletions were described in Beckwith-Wiedemann syndrome and WT (Prawitt et al., 2005; Sparago et al., 2007) . Other methylated CTCF targets were found in the genes AWT1 or WT1-AS in WT (Hancock et al., 2007) , Bcl6 in B cell lymphomas (Lai et al., 2010 ), p53, pRb (De La RosaVelazquez et al., 2007 , ARF (Tam et al., 2003; Rodriguez et al., 2010) , INK4B, BRCA1 (Butcher et al., 2004; Butcher et al., 2007; Xu et al., 2010) and Rasgrf1 (Yoon et al., 2005) . We describe below the rare cases of point mutations affecting the CTCF protein.
Invasive ductal breast carcinoma, grade 2
Note G2 grade tumor, no protein detected (Aulmann et al., 2003) . 
